Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.

Neurology - 22 May 2007

Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard M-A, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon J-M, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre J-Y, Hoang-Xuan K

Abstract excerpt

OBJECTIVE: To evaluate the predictive impact of chromosome 1p/19q deletions on the response and outcome of progressive low-grade gliomas (LGG) treated with up-front temozolomide (TMZ) chemotherapy. METHODS: Adult patients with measurable, progressive LGG (WHO grade II) treated with TMZ delivered...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Chromosomes, Human, Pair 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 19

Share to Dacarbazine

Share to Glioma

Share to Loss of Heterozygosity

Share to Neoplasm Recurrence, Local

Share to Temozolomide

Source

Identifiers

PMID: 17515545
DOI: 10.1212/01.wnl.0000262034.26310.a2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17515545-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.PMID 17515545Read ↗

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.Semantic proximity Read ↗

Current management of low-grade gliomas.Semantic proximity Read ↗

Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.Semantic proximity Read ↗

Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.Semantic proximity Read ↗

Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic OligodendrogliomasSemantic proximity Read ↗

Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.Semantic proximity Read ↗

Oligodendroglial Tumors: Refinement of Candidate Regions on Chromosome Arm 1p and Correlation of 1p/19q Status with SurvivalSemantic proximity Read ↗

IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.Semantic proximity Read ↗

Chromosome 1p loss: A favorable prognostic factor in low‐grade gliomasSemantic proximity Read ↗

Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status?Semantic proximity Read ↗

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.Semantic proximity Read ↗

Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.